Facilitating the operational readiness of the NHS for the in-house manufacture and delivery of autologous cell therapy [210] | ORKG Ask

We use cookies to provide a better user experience.

Data Protection

Related items

Estimation of manufacturing development costs of cell-based therapies: a feasibility study

ten Ham, Renske M.T.
Nievaart, Julianne C.
Hoekman, Jarno
Cooper, Rachel S.
Frederix, Geert W.J.
Leufkens, Hubert G.M.
Klungel, Olaf H.
Ovelgönne, Hans
Hoefnagel, Marcel H.N.
Turner, Marc L.
Mountford, Joanne C.
Innovation Studies
Pharmacoepidemiology and Clinical Pharmacology
Afd Pharmacoepi & Clinical Pharmacology
Innovation and Sustainability

August 2021

Background aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden dis...

Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability

Hourd, Paul
Ginty, Patrick
Chandra, Amit
Williams, David J.

August 2014

AbstractManufacturing of more-than-minimally manipulated autologous cell therapies presents a number...

Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability

Paul Hourd (1250460)
Patrick J. Ginty (7129373)
Amit Chandra (1249059)
David Williams (1248024)

January 2014

Manufacturing of more-than-minimally manipulated autologous cell therapies presents a number of uniq...

A model-based approach to address the commercialisation challenges of autologous cell therapies

Lam, C

January 2021

Whilst many cell therapy products have been approved over the last 20 years, very few have achieved ...

What does cell therapy manufacturing cost?: A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Ten Ham, Renske M T
Hövels, Anke M
Hoekman, Jarno
Frederix, Geert W J
Leufkens, Hubert G M
Klungel, Olaf H
Jedema, Inge
Veld, Sabrina A J
Nikolic, Tatjana
Van Pel, Melissa
Zwaginga, Jaap J
Lin, Fong
de Goede, Anna L
Schreibelt, Gerty
Budde, Sandy
de Vries, I Jolanda M
Wilkie, Gwen M
Dolstra, Harry
Ovelgönne, Hans
Meij, Pauline
Mountford, Joanne C
Turner, Marc L
Hoefnagel, Marcel H N

January 2020

BACKGROUND AIMS: Recent technical and clinical advances with cell-based therapies (CBTs) hold great ...

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.

Ham, R.M.T. Ten
Hövels, A.M.
Hoekman, J.
Frederix, G.W.
Leufkens, H.G.
Klungel, O.H.
Jedema, I.
Veld, S.A.J.
Nikolic, T.
Pel, M. van
Zwaginga, J.J.
Lin, F.
Goede, A.L. de
Schreibelt, G.
Budde, S.M.S.
Vries, I.J.M. de
Wilkie, G.M.
Dolstra, H.
Ovelgönne, H.
Meij, P.
Mountford, J.C.
Turner, M.L.
Hoefnagel, M.H.N.

January 2020

BACKGROUND AIMS: Recent technical and clinical advances with cell-based therapies (CBTs) hold great ...

Estimation of manufacturing development costs of cell-based therapies : a feasibility study

ten Ham, Renske M.T.
Nievaart, Julianne C.
Hoekman, Jarno
Cooper, Rachel S.
Frederix, Geert W.J.
Leufkens, Hubert G.M.
Klungel, Olaf H.
Ovelgönne, Hans
Hoefnagel, Marcel H.N.
Turner, Marc L.
Mountford, Joanne C.

August 2021

Background aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden dis...

Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products

Paul Hourd (1250460)
Amit Chandra (1249059)
David Alvey (7129370)
Patrick J. Ginty (7129373)
Mark McCall (1253622)
Elizabeth Ratcliffe (1250265)
Erin Rayment (7129379)
David Williams (1248024)

January 2014

Academic centres, hospitals and small companies, as typical development settings for UK regenerative...

Estimation of manufacturing development costs of cell-based therapies: a feasibility study

ten Ham, Renske M.T.
Nievaart, Julianne C.
Hoekman, Jarno
Cooper, Rachel S.
Frederix, Geert W.J.
Leufkens, Hubert G.M.
Klungel, Olaf H.
Ovelgönne, Hans
Hoefnagel, Marcel H.N.
Turner, Marc L.
Mountford, Joanne C.
Innovation Studies
Pharmacoepidemiology and Clinical Pharmacology
Afd Pharmacoepi & Clinical Pharmacology
Innovation and Sustainability

August 2021

Background aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden dis...

What does cell therapy manufacturing cost?: A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Ten Ham, Renske M T
Hövels, Anke M
Hoekman, Jarno
Frederix, Geert W J
Leufkens, Hubert G M
Klungel, Olaf H
Jedema, Inge
Veld, Sabrina A J
Nikolic, Tatjana
Van Pel, Melissa
Zwaginga, Jaap J
Lin, Fong
de Goede, Anna L
Schreibelt, Gerty
Budde, Sandy
de Vries, I Jolanda M
Wilkie, Gwen M
Dolstra, Harry
Ovelgönne, Hans
Meij, Pauline
Mountford, Joanne C
Turner, Marc L
Hoefnagel, Marcel H N

January 2020

BACKGROUND AIMS: Recent technical and clinical advances with cell-based therapies (CBTs) hold great ...

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.

Ham, R.M.T. Ten
Hövels, A.M.
Hoekman, J.
Frederix, G.W.
Leufkens, H.G.
Klungel, O.H.
Jedema, I.
Veld, S.A.J.
Nikolic, T.
Pel, M. van
Zwaginga, J.J.
Lin, F.
Goede, A.L. de
Schreibelt, G.
Budde, S.M.S.
Vries, I.J.M. de
Wilkie, G.M.
Dolstra, H.
Ovelgönne, H.
Meij, P.
Mountford, J.C.
Turner, M.L.
Hoefnagel, M.H.N.

January 2020

BACKGROUND AIMS: Recent technical and clinical advances with cell-based therapies (CBTs) hold great ...

Estimation of manufacturing development costs of cell-based therapies : a feasibility study

ten Ham, Renske M.T.
Nievaart, Julianne C.
Hoekman, Jarno
Cooper, Rachel S.
Frederix, Geert W.J.
Leufkens, Hubert G.M.
Klungel, Olaf H.
Ovelgönne, Hans
Hoefnagel, Marcel H.N.
Turner, Marc L.
Mountford, Joanne C.

August 2021

Background aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden dis...

Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products

Paul Hourd (1250460)
Amit Chandra (1249059)
David Alvey (7129370)
Patrick J. Ginty (7129373)
Mark McCall (1253622)
Elizabeth Ratcliffe (1250265)
Erin Rayment (7129379)
David Williams (1248024)

January 2014

Academic centres, hospitals and small companies, as typical development settings for UK regenerative...

Estimation of manufacturing development costs of cell-based therapies: a feasibility study

ten Ham, Renske M.T.
Nievaart, Julianne C.
Hoekman, Jarno
Cooper, Rachel S.
Frederix, Geert W.J.
Leufkens, Hubert G.M.
Klungel, Olaf H.
Ovelgönne, Hans
Hoefnagel, Marcel H.N.
Turner, Marc L.
Mountford, Joanne C.
Innovation Studies
Pharmacoepidemiology and Clinical Pharmacology
Afd Pharmacoepi & Clinical Pharmacology
Innovation and Sustainability

August 2021

Background aims: Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden dis...